Cellectar Biosciences Files 8-K
Ticker: CLRB · Form: 8-K · Filed: Oct 6, 2025 · CIK: 1279704
| Field | Detail |
|---|---|
| Company | Cellectar Biosciences, Inc. (CLRB) |
| Form Type | 8-K |
| Filed Date | Oct 6, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, corporate-events, financials
TL;DR
Cellectar filed an 8-K on Oct 6, 2025, covering Reg FD, other events, and financials.
AI Summary
Cellectar Biosciences, Inc. filed an 8-K on October 6, 2025, reporting on various events. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, incorporated in Delaware, is based in Florham Park, NJ, and operates in the Pharmaceutical Preparations sector.
Why It Matters
This 8-K filing provides updates on Cellectar Biosciences' corporate activities, including regulatory disclosures and financial information, which are important for investors to monitor the company's status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting on standard corporate events and disclosures, not indicating any immediate significant risks.
Key Players & Entities
- Cellectar Biosciences, Inc. (company) — Registrant
- October 6, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Florham Park, NJ (location) — Principal Executive Offices
- NOVELOS THERAPEUTICS, INC. (company) — Former Company Name
- COMMON HORIZONS INC (company) — Former Company Name
FAQ
What is the primary purpose of this 8-K filing for Cellectar Biosciences, Inc.?
This 8-K filing serves multiple purposes, including Regulation FD Disclosure, reporting on Other Events, and providing Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on October 6, 2025.
In which state is Cellectar Biosciences, Inc. incorporated?
Cellectar Biosciences, Inc. is incorporated in Delaware.
What is the business address of Cellectar Biosciences, Inc.?
The principal executive offices of Cellectar Biosciences, Inc. are located at 100 Campus Drive, Florham Park, NJ, 07932.
What were some of Cellectar Biosciences, Inc.'s former company names?
Cellectar Biosciences, Inc. was formerly known as NOVELOS THERAPEUTICS, INC. and COMMON HORIZONS INC.
Filing Stats: 977 words · 4 min read · ~3 pages · Grade level 14.1 · Accepted 2025-10-06 07:15:48
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share CLRB NASDAQ Check the a
Filing Documents
- tm2528016d1_8k.htm (8-K) — 29KB
- tm2528016d1_ex99-1.htm (EX-99.1) — 21KB
- tm2528016d1_ex99-1img001.jpg (GRAPHIC) — 9KB
- 0001104659-25-096928.txt ( ) — 231KB
- clrb-20251006.xsd (EX-101.SCH) — 3KB
- clrb-20251006_lab.xml (EX-101.LAB) — 33KB
- clrb-20251006_pre.xml (EX-101.PRE) — 22KB
- tm2528016d1_8k_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure On October 6, 2025, Cellectar Biosciences, Inc. (the "Company") issued a press release announcing that after a scientific advice procedure, the Scientific Advice Working Party ("SAWP") of the European Medicines Agency ("EMA") advised that filing for a Conditional Marketing Authorization ("CMA") for iopofosine I 131 as a treatment for post-Bruton Tyrosine Kinase inhibitor ("BTKi") refractory patients with Waldenstrom macroglobulinemia ("WM") could be acceptable for a CMA. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Item 7.01 Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Item8.01. Other Events On October 6, 2025, the Company announced that after a scientific advice procedure, SAWP advised that filing for a CMA for iopofosine I 131 as a treatment for post- BTKi refractory patients with WM could be acceptable for a CMA. There is no guarantee of CMA approval; however, if iopofosine I 131 is granted a CMA, it could potentially begin to be commercially available in the 30 countries represented by the EMA as early as 2027. The Company's decision to file for CMA in Europe follows SAWP's advice on the patient population for which iopofosine I 131 is acceptable for a CMA, particularly a discussion on a post BTKi patient population, consistent with the majority of the patients (>70%) enrolled in the CLOVER WaM Phase 2 study. The Company's briefing document to the SAWP included iopofosine I 131's safety database, CLOVER WaM cl
Financial Statements and Exhibits
Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release, dated October 6, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELLECTAR BIOSCIENCES, INC. Date: October 6, 2025 By: / s/ Chad J. Kolean Chad J. Kolean Chief Financial Officer